This inventor holds 5 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 4 EPO patents. Top assignees: The University of Queensland, Seattle Children's Hospital. Active years: 2017-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- St Lucia, AU (2017 - 2019)
- Balmoral, AU (2018 - 2021)
Company Filing History:
5 out of 345 
1 out of 89 
Years Active: 2017-2025
Title: Matt Trau: Innovator in Epigenetics and Biofragment Technology
Introduction
Matt Trau is a prominent inventor based in Balmoral, Australia. He has made significant contributions to the fields of epigenetics and biofragment technology. With a total of 5 patents to his name, Trau's work is at the forefront of scientific innovation.
Latest Patents
One of Trau's latest patents is focused on an epigenetic biomarker. This biomarker comprises clustered methylated genomic DNA that can self-assemble to form complexes with distinct physicochemical properties compared to genomic DNA lacking such clusters. The patent also includes methods, systems, compositions, and kits that utilize these properties for detecting clustered methylated genomic DNA, particularly for assessing the likelihood of cancer presence.
Another significant patent involves cell-free biofragment compositions and related systems, devices, and methods. This disclosure pertains to biofragment compositions that consist of bioparticle fragments and at least one heterologous antigen-binding molecule. The biofragment is typically derived from a larger, intact bioparticle that expresses the antigen-binding molecule at its surface. This innovation enhances solubility, facilitating assays for antigen detection without the need for additional detection reagents, such as animal-derived antibodies.
Career Highlights
Throughout his career, Matt Trau has worked with esteemed institutions, including The University of Queensland and Seattle Children's Hospital. His work has significantly impacted the scientific community, particularly in the areas of cancer detection and bioassay development.
Collaborations
Trau has collaborated with notable professionals in his field, including Sakandar Rauf and Gerard A. Cangelosi. These collaborations have further enriched his research and innovation efforts.
Conclusion
Matt Trau's contributions to epigenetics and biofragment technology exemplify the spirit of innovation in modern science. His patents and collaborations continue to pave the way for advancements in cancer detection and diagnostic methods.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile